These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 7593495)

  • 41. Role of progesterone in capillary permeability in hyperstimulated rats.
    Ujioka T; Matsuura K; Kawano T; Okamura H
    Hum Reprod; 1997 Aug; 12(8):1629-34. PubMed ID: 9308783
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Timed unilateral ovarian follicular aspiration prior to administration of human chorionic gonadotrophin for the prevention of severe ovarian hyperstimulation syndrome in in-vitro fertilization: a prospective randomized study.
    Egbase PE; Makhseed M; Al Sharhan M; Grudzinskas JG
    Hum Reprod; 1997 Dec; 12(12):2603-6. PubMed ID: 9455821
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prediction of Ovarian Hyperstimulation Syndrome in Patients Treated with Corifollitropin alfa or rFSH in a GnRH Antagonist Protocol.
    Griesinger G; Verweij PJ; Gates D; Devroey P; Gordon K; Stegmann BJ; Tarlatzis BC
    PLoS One; 2016; 11(3):e0149615. PubMed ID: 26950065
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
    Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
    Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preventing ovarian hyperstimulation syndrome: cabergoline versus coasting.
    Esinler I; Bozdag G; Karakocsokmensuer L
    Arch Gynecol Obstet; 2013 Nov; 288(5):1159-63. PubMed ID: 23677417
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment with buserelin, an agonist of gonadotropin-releasing hormone, suppresses ovarian hyperstimulation syndrome induced in rabbits.
    Oshima K; Suzuki K; Makita S; Yoshida Y
    Pharmacology; 2004 Nov; 72(3):184-9. PubMed ID: 15452367
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome.
    Soares SR; Gómez R; Simón C; García-Velasco JA; Pellicer A
    Hum Reprod Update; 2008; 14(4):321-33. PubMed ID: 18385260
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Relationship between letrozole administration during the luteal phase after oocyte retrieval and the early-stage ovarian hyperstimulation syndrome oocurrence].
    He Q; Xu J; Cui S; Li H; Zhang C
    Zhonghua Fu Chan Ke Za Zhi; 2014 Dec; 49(12):909-13. PubMed ID: 25608991
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Administration of low-dose LH induces ovulation and prevents vascular hyperpermeability and vascular endothelial growth factor expression in superovulated rats.
    Gómez R; Lima I; Simón C; Pellicer A
    Reproduction; 2004 Apr; 127(4):483-9. PubMed ID: 15047939
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of gonadotrophin-releasing hormone analogues and human chorionic gonadotrophin for the induction of ovulation and prevention of ovarian hyperstimulation syndrome: a case-control study.
    Lewit N; Kol S; Manor D; Itskovitz-Eldor J
    Hum Reprod; 1996 Jul; 11(7):1399-402. PubMed ID: 8671474
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New insights in mechanisms for development of ovarian hyperstimulation syndrome.
    Kasum M
    Coll Antropol; 2010 Sep; 34(3):1139-43. PubMed ID: 20977119
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of varying doses of tamoxifen on ovarian histopathology, serum VEGF, and endothelin 1 levels in ovarian hyperstimulation syndrome: an experimental study.
    Pala Ş; Atilgan R; Ozkan ZS; Kavak SB; Ilhan N; Akpolat N; Sapmaz E
    Drug Des Devel Ther; 2015; 9():1761-6. PubMed ID: 25848212
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Severe ovarian hyperstimulation syndrome modifies early maternal serum beta-human chorionic gonadotropin kinetics, but obstetrical and neonatal outcomes are not impacted.
    Choux C; Barberet J; Ginod P; Cottenet J; Bruno C; Benzénine E; Sagot P; Fauque P
    Fertil Steril; 2017 Oct; 108(4):650-658.e2. PubMed ID: 28911926
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A potential role of endoplasmic reticulum stress in development of ovarian hyperstimulation syndrome.
    Takahashi N; Harada M; Hirota Y; Zhao L; Yoshino O; Urata Y; Izumi G; Takamura M; Hirata T; Koga K; Wada-Hiraike O; Fujii T; Osuga Y
    Mol Cell Endocrinol; 2016 Jun; 428():161-9. PubMed ID: 27032713
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cabergoline for preventing ovarian hyperstimulation syndrome.
    Tang H; Hunter T; Hu Y; Zhai SD; Sheng X; Hart RJ
    Cochrane Database Syst Rev; 2012 Feb; (2):CD008605. PubMed ID: 22336848
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dual inhibition of angiotensin converting enzyme and neutral endopeptidase produces effective blood pressure control in spontaneously hypertensive rats.
    Kostova E; Jovanoska E; Zafirov D; Jakovski K; Maleska V; Slaninka-Miceska M
    Bratisl Lek Listy; 2005; 106(12):407-11. PubMed ID: 16642666
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dopamine agonists in prevention of ovarian hyperstimulation syndrome.
    Kasum M; Vrčić H; Stanić P; Ježek D; Orešković S; Beketić-Orešković L; Pekez M
    Gynecol Endocrinol; 2014; 30(12):845-9. PubMed ID: 25093428
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cycles triggered with GnRH agonist: exploring low-dose HCG for luteal support.
    Castillo JC; Dolz M; Bienvenido E; Abad L; Casañ EM; Bonilla-Musoles F
    Reprod Biomed Online; 2010 Feb; 20(2):175-81. PubMed ID: 20113955
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Double GnRH-antagonist dose before HCG administration may prevent OHSS in oocyte-donor cycles: a pilot study.
    Prapas Y; Panagiotidis I; Kalogiannidis I; Gjata E; Papatheodorou A; Prapa S; Kasapi L; Goudakou M; Prapas N
    Reprod Biomed Online; 2010 Aug; 21(2):159-65. PubMed ID: 20627811
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Embryo freezing for preventing Ovarian Hyperstimulation Syndrome.
    D'Angelo A; Amso N
    Cochrane Database Syst Rev; 2002; (2):CD002806. PubMed ID: 12076453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.